Chris Peetz is a co-founder of Mirum and serves as president and chief executive officer.
Chris has been an entrepreneur-in-residence at Frazier Healthcare Partners since May 2017. Prior to joining Mirum, Chris served as the chief executive officer of Flashlight Therapeutics, Inc. From May 2014 to December 2016, he served as chief financial officer and head of corporate development at Tobira, which was acquired by Allergan plc, in November 2016. Prior to joining Tobira, Chris served as vice president, finance and corporate development of Jennerex Biotherapeutics. Prior to Jennerex, Chris held various positions at Onyx Pharmaceuticals, Inc. (now Amgen Inc.), including corporate strategy, marketing, product lifecycle management, and financial planning. Prior to Onyx, Chris provided merger and acquisition advisory services at LaSalle Corporate Finance, a part of ABN AMRO, and held positions at Abgenix Inc. and Solazyme Inc. He also serves as a member of the board of directors of Alpine Immune Sciences, Inc., a public immunotherapy company, since April 2018.
Chris received an M.B.A. from Stanford Graduate School of Business and a B.S.B.A. in Finance, International Business and French from Washington University in St. Louis.
What is Christopher Peetz's net worth?
The estimated net worth of Christopher Peetz is at least $2.66 million as of January 8th, 2024. Mr. Peetz owns 110,125 shares of Mirum Pharmaceuticals stock worth more than $2,661,721 as of April 23rd. This net worth evaluation does not reflect any other investments that Mr. Peetz may own. Additionally, Mr. Peetz receives a salary of $1,090,000.00 as CEO at Mirum Pharmaceuticals. Learn More about Christopher Peetz's net worth.
How old is Christopher Peetz?
What is Christopher Peetz's salary?
How do I contact Christopher Peetz?
Has Christopher Peetz been buying or selling shares of Mirum Pharmaceuticals?
Christopher Peetz has not been actively trading shares of Mirum Pharmaceuticals during the last ninety days. Most recently, Christopher Peetz sold 5,209 shares of the business's stock in a transaction on Monday, January 8th. The shares were sold at an average price of $28.03, for a transaction totalling $146,008.27. Following the completion of the sale, the chief executive officer now directly owns 110,125 shares of the company's stock, valued at $3,086,803.75. Learn More on Christopher Peetz's trading history.
Who are Mirum Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Mirum Pharmaceuticals?
During the last twelve months, Mirum Pharmaceuticals insiders bought shares 5 times. They purchased a total of 166,678 shares worth more than $4,424,479.85. During the last twelve months, insiders at the sold shares 14 times. They sold a total of 56,827 shares worth more than $1,621,582.31. The most recent insider tranaction occured on March, 27th when CFO Eric Bjerkholt bought 2,000 shares worth more than $49,600.00. Insiders at Mirum Pharmaceuticals own 24.1% of the company.
Learn More about insider trades at Mirum Pharmaceuticals. Information on this page was last updated on 3/27/2024.
